Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib
Paziente con carcinoma mammario metastatico, HER2-positivo, resistente a trastuzumab e pertuzumab ma responsivo a lapatinib
DOI:
https://doi.org/10.19156/abtpn.2018.0044Keywords:
Metastatic breast cancer, HER2, Lapatinib, Trastuzumab resistance, Pertuzumab resistanceAbstract
Lapatinib is an intracellular tyrosine kinase inhibitor of EGFR (ErbB1) and HER2 (ErbB2) receptors, approved for the treatment of metastatic breast carcinoma pre-treated with anti-HER2 antibodies. We report the case of a 60-year-old woman diagnosed with metastatic breast neoplasm, HER2-positive, progressing after treatment with trastuzumab, pertuzumab and T-DM1, who obtained a regression of hepatic metastases after treatment with lapatinib-capecitabine (Oncology).
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Authors contributing to AboutOpen agree to publish their articles under the Creative Commons NonCommercial 4.0 International License (CC BY-NC 4.0), which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.
